Characteristic | Confirmed HAE (n = 254) | Suspected HAE (n = 1299) |
---|---|---|
Duration of follow-up period (months) | Â | Â |
 Mean (SD) | 50.0 (34.3) | 45.9 (33.1) |
 Median (IQR) | 45.7 (19.4–72.0) | 37.8 (16.9–70.5) |
Number of visits during the follow-up period | Â | |
 Mean (SD) | 1.14 (1.10) | 1.02 (0.91) |
 Median (IQR) | 0.77 (0.40–1.48) | 0.75 (0.34–1.46) |
Prescriptions for HAE-specific medication | ||
 Patients with ≥ 1 prescription, n (%) | 79 (31.1) | 30 (2.3) |
 Prescriptions PPPM |  |  |
  Mean (SD) | 0.18 (0.18) | 0.13 (0.23) |
  Median (IQR) | 0.10 (0.05–0.29) | 0.07 (0.03–0.11) |
 Type of treatment, n (%) |  |  |
  C1 inhibitor | 45 (17.7) | 5 (0.4) |
  Ecallantide | 11 (4.3) | 3 (0.2) |
  Icatibant | 26 (10.2) | 4 (0.3) |
  Androgen | 35 (13.8) | 22 (1.7) |
HAE attack diagnosis and/or procedure codes | ||
 Patients with evidence of ≥ 1 HAE attack, n (%) | 106 (41.7) | 389 (29.9) |
 HAE attacks PPPM |  |  |
  Mean (SD) | 0.05 (0.09) | 0.03 (0.07) |
  Median (IQR) | 0.02 (0.00–0.06) | 0.00 (0.00–0.03) |